Answers are grounded in this paper and cite their sources.
The addition of immunosuppressive therapy to intensive supportive care in patients with high-risk IgA nephropathy did not significantly improve the outcome, and during the 3-year study phase, more adverse effects were observed among the patients who received immunosuppressive therapy, with no change in the rate of decrease in the eGFR. (Funded by the German Federal Ministry of Education and Research; STOP-IgAN ClinicalTrials.gov number, NCT00554502.).
No takes yet. Share an insight, caveat, or question.
Rauen et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: